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ABSTRACT 
 During M phase, Endosulfine (Endos) family proteins are phosphorylated by Greatwall kinase 
(Gwl), and the resultant pEndos inhibits the phosphatase PP2A-B55, which would otherwise 
prematurely reverse many CDK-driven phosphorylations. We show here that PP2A-B55 is the 
enzyme responsible for dephosphorylating pEndos during M phase exit.  The kinetic 
parameters for PP2A-B55’s  action on pEndos are orders of magnitude lower than those for 
CDK-phosphorylated substrates, suggesting a simple model for PP2A-B55 regulation that we 
call inhibition by unfair competition.  As the name suggests, during M phase PP2A-B55’s  
attention is diverted to pEndos, which binds much more avidly and is dephosphorylated more 
slowly than other substrates.  When Gwl is inactivated during the M phase-to-interphase 
transition, the dynamic balance changes: pEndos dephosphorylated by PP2A-B55 cannot be 
replaced, so the phosphatase can refocus its attention on CDK-phosphorylated substrates.  This 
mechanism explains simultaneously how PP2A-B55 and Gwl together regulate pEndos, and 
how pEndos controls PP2A-B55. 
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INTRODUCTION 
Entry of cells into M phase of mitosis or meiosis requires the phosphorylation of 
thousands of sites on hundreds of proteins (16, 18, 48, 63).  Many of these sites are substrates 
of cyclin-dependent kinases (CDKs), most notably MPF (M phase-promoting factor; CDK1-
Cyclin B).  CDK  phosphosites  are  “proline-directed,” being phosphorylated at serine or 
threonine followed by proline (31, 62).  These M phase-specific phosphorylations must 
eventually be removed so that mitotic/meiotic cells can reset to interphase.  PP2A-B55 
(heterotrimeric protein phosphatase 2A composed of a catalytic C subunit, a structural A 
subunit, and a B55-type regulatory subunit) is the phosphatase responsible for removing many 
key CDK-generated phosphorylations at the conclusion of M phase (9, 12, 52, 55, 56, 72).   
The  circuitry’s  basic  logic  suggests that PP2A-B55 activity must be downregulated 
when cells go into M phase; if not, the phosphorylations catalyzed by MPF would be 
prematurely removed, preventing M phase entry (12, 47).  Indeed, a regulatory module that 
turns off PP2A-B55 specifically during M phase has recently been characterized (Figure 1).  In 
brief, MPF phosphorylates and thereby activates the Greatwall kinase (Gwl) (5, 96).  Activated 
Gwl phosphorylates small proteins of the Endosulfine family [Endos; (23, 57)] at a unique, 
highly conserved site.  Gwl-phosphorylated Endos (pEndos) binds to and inactivates PP2A-
B55, thus protecting a major class of CDK-governed phosphorylations from premature 
removal during M phase [reviewed in (24, 33, 50, 51)].  The GwlpEndos ⊣ PP2A-B55 
pathway is critical for M phase entry and maintenance in frog egg extracts, starfish oocytes, 
and in many cell types in culture or within metazoan organisms (2, 8, 28, 49, 86, 95). 
In this report, we explore how this M phase activation system is reversed when cells 
exit mitosis or meiosis.  Not only must CDK-dependent phosphorylations be removed by 
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newly reactivated PP2A-B55, but also Gwl and pEndos must be inactivated at the end of M 
phase by the removal of their stimulatory phosphorylations  (Figure 1).  If Gwl were to remain 
active, it would continually keep Endos phosphorylated; PP2A-B55 would stay inactive and 
the system would remain in M phase because mitotic phosphorylations could not be removed.  
On the other hand, if Gwl alone were inactivated but pEndos were to stay phosphorylated, M 
phase would again be maintained.  We focus here on the second part of this equation by 
identifying the phosphatase that dephosphorylates and turns off pEndos. 
At the onset of these investigations, we thought that pEndos inactivation could not be 
achieved solely by PP2A-B55.  Not only is the Gwl-phosphorylated pEndos site not proline-
directed, as are CDK targets, but also a system based only on PP2A-B55 would be closed and 
futile: If PP2A-B55 is inactive during M phase, how could this dead enzyme turn itself back on?  
Clearly, the “anti-Endos”  phosphatase(s) targeting Gwl-phosphorylated pEndos must instead be 
active during at least late M phase.  As we will show, the expectation that anti-Endos is active 
during M phase has been borne out.  However, counterintuitively we found that almost all of 
this anti-Endos activity is contributed by PP2A-B55.  This surprising conclusion is made 
possible because the kinetic parameters of this enzyme for pEndos and for CDK-
phosphorylated substrates are very different.  Based on this divergence, we suggest a 
straightforward mechanism we call inhibition by unfair competition that explains how pEndos 
acts both as an inhibitor and a substrate of PP2A-B55, and how this phosphatase can 
simultaneously  be  “on”  for  some  substrates  but  “off”  for  others.  This mechanism may have 
broad implications for the control of other cellular protein phosphatases. 
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RESULTS 
As a first step in identifying the phosphatase(s) that dephosphorylate and inactivate 
pEndos, we assayed various cellular extracts for the release of 32P from recombinant pEndos 
previously phosphorylated by Gwl.  The extracts’  anti-Endos activities were compared with 
their phosphatase activities against other representative substrates used as internal controls.  
Most often, we used the recombinant polypeptide CDKS (CDK substrate) phosphorylated in 
vitro by CDK1-Cyclin A (see Materials and Methods).  Previous studies have shown that 
dephosphorylation at this site is specifically catalyzed by PP2A-B55 (9, 55); hereafter we 
reference this dephosphorylation as the “anti-CDKS” activity.  We obtained very similar results 
in several experiments using a different CDK substrate that includes Fizzy phosphorylated at 
Ser50, which is also a specific target of PP2A-B55 (9, 55-57). 
 
Anti-Endos remains active during M phase 
We initiated our search for the anti-Endos phosphatase by asking if this activity has the 
basic characteristic predicted by the logic of the system: In contrast with the anti-CDKS 
activity of PP2A-B55, which is off during M phase, the anti-Endos phosphatase should remain 
active during M phase to permit subsequent M phase exit.  This question could be addressed 
readily using extracts of Xenopus eggs, which are prepared in an M phase state but can be 
induced to exit M phase by addition of Ca2+ (60, 61, 82).  Figure 2A shows that in accordance 
with this prediction, considerable anti-Endos activity is indeed seen during M phase.  The level 
is roughly half that seen in interphase; as will be explained below, we believe this difference 
results from competition between exogenous radiolabeled pEndos and endogenous unlabeled 
pEndos present in M phase but not interphase.  As expected from previous studies (9, 55), anti-
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CDKS activity (i.e., PP2A-B55) was completely blocked in M phase extracts and strongly 
induced by treatment with Ca2+ (Figure 2A).  
 
The predominant anti-Endos activity is associated with PP2A, PP4, or PP6 
We next characterized the sensitivity of the anti-Endos phosphatase in concentrated 
extracts (from Xenopus eggs and human, fly, or mouse tissue culture cells) to common 
phosphatase inhibitors. The properties of anti-Endos studied in all of these extracts were nearly 
interchangeable.  All of the activity in all extracts tested was suppressed by relatively low 
doses of okadaic acid or calyculin A (Figure 2B and Figure 2 - figure supplement 1), but was 
completely resistant to the calcineurin (PP2B) inhibitor cyclosporin A (data not shown).  These 
results indicate that the enzyme(s) targeting the Gwl site in Endos belong to the PPP family of 
phospho-serine/threonine protein phosphatases which include PP1, PP2A, PP4, PP5, or PP6 
(79).  
PP1 and PP5 are ~10,000-fold more resistant to the inhibitor fostriecin than the 
PP2A/PP4/PP6 group of enzymes (79).  In all extracts examined, the majority of anti-Endos 
activity was sensitive to the same doses of fostriecin that inhibit PP2A-B55’s anti-CDKS 
activity (Figure 2C and Figure 2 – figure supplement 2).  Anti-Endos and anti-CDKS 
activities were both considerably more sensitive to fostriecin than were the dephosphorylations 
of two other substrates, CDK-phosphorylated histones H1v1.0, which is substantially targeted 
by PP1-like enzymes (65, 67), and histone H3, which is apparently a substrate for both a 
fostriecin-sensitive and a fostriecin-resistant phosphatase.  The predominant anti-Endos activity 
in many cell types (~70-90% of the total depending on the experiment) is thus due to PP2A, 
PP4, or PP6.  Because the major anti-Endos activity displays closely similar sensitivities to 
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okadaic acid or fostriecin when comparing M phase and interphase frog egg extracts, it appears 
that the same phosphatase is responsible for this activity during both cell cycle stages (Figure 
2 – figure supplements 1C and 2A). 
A minor fraction of anti-Endos is nonetheless fostriecin-resistant; this part of the 
activity is labile and is seen in some extract preparations (Figure 2 – figure supplement 2A-C, 
F) but not others (Figure 2C and Figure 2 – figure supplement 2D, E).  This secondary 
activity, possibly due to some form of PP1, is likely responsible for the modest okadaic acid 
resistance of anti-Endos (relative to anti-CDKS) seen in concentrated Xenopus extracts (Figure 
2 – figure supplement 1C), where the proportion of fostriecin-resistant activity is highest 
(Figure 2 – figure supplement 2A,B).  In the Discussion, we argue that this minor component 
of anti-Endos is unlikely to be of great physiological importance; in the remainder of the 
Results, we thus focus on the predominant fostriecin-sensitive enzyme. 
 
Anti-Endos and anti-CDKS phosphatase activities differ in many properties 
In spite of the fact that anti-Endos and anti-CDKS are both associated with the same 
highly related subfamily of PPP phosphatases including PP2A, PP4, and PP6, further 
experiments revealed clear divergences in the behavior of these two phosphatase activities. 
First, we characterized the response of anti-Endos and anti-CDKS activities to 
tautomycetin and its relative tautomycin.  These drugs have been reported to be much more 
effective as inhibitors of PP1 than PP2A (26, 38, 53).  This conclusion was verified in our own 
system using purified enzymes (Figure 2 – figure supplement 3A) and by the tautomycetin 
sensitivity of phosphatase activity in extracts against the PP1-specific substrate Histone H1v1.0 
(Figure 2D).  In contrast, the anti-Endos activity in all extracts tested is 6-10-fold more 
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resistant to tautomycetin than is anti-CDKS (Figure 2D and Figure 2 – figure supplement 
3B-F).  This result is surprising because we had not anticipated the existence of a PPP family 
phosphatase more tautomycetin-resistant than PP2A-B55.  The tautomycetin/tautomycin 
resistance of anti-Endos is due to the major, fostriecin-sensitive component, because extracts 
lacking the labile fostriecin-resistant enzyme are still resistant to tautomycetin (the extracts 
used in Figure 2C and Figure 2D are identical). 
Second, we found that in contrast to anti-CDKS, anti-Endos is relatively unaffected by 
the presence of constitutively activated Endos.  Endosulfine thiophosphorylated by Gwl acts in 
vitro as a specific inhibitor of PP2A-B55’s  anti-CDKS activity; this effect is also observed 
using Endos bearing a phosphomimetic mutation of the Gwl target site (23, 39, 57).  However, 
the anti-Endos activity in extracts is substantially resistant to inhibition by phosphomimetic 
Drosophila Endos (S68D) (Figure 2E and Figure 2 – figure supplement 4). 
Finally, it has previously been reported that the dilution of cellular extracts leads to 
large increases in the specific activity of protein phosphatases, possibly caused by the 
decreased association, due to mass action, of the phosphatase with weak inhibitors in the 
extracts (13, 56).  We have verified this dilution effect for anti-CDKS and anti-H1v1.0, but in 
contrast, anti-Endos activity is very much less affected by extract dilution (Figure 2F and 
Figure 2 – figure supplement 5).   
The data to this point suggest that the major anti-Endos enzyme is some form of PP2A, 
PP4, or PP6.  As we anticipated, anti-Endos is clearly differentiated from PP2A-B55 (anti-
CDKS) in terms of its constitutive activity during M phase.  Anti-Endos and anti-CDKS also 
diverge strongly in terms of their relative sensitivities to tautomycetin, phosphomimetic Endos, 
and extract dilution.   
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Depletion or mutation of PP2A-B55 removes most anti-Endos activity 
To pinpoint which of the candidate phosphatases targets the Gwl phosphosite on 
pEndos, we examined anti-Endos activity in extracts of cultured cells depleted for phosphatase 
subunits (Figure 3).  Treatment of Drosophila S2 cells with dsRNAs for the single PP2A 
catalytic subunit gene in the fly genome (called mts) caused the loss of 70-75% of the anti-
Endos activity (Figure 3A).  Success of the RNAi was verified by Western blot (Figure 3B), 
and by the almost complete loss of anti-CDKS activity in the dsRNA-treated cells (Figure 3A).  
Depletion of the A (structural) subunit of PP2A also caused substantial loss of anti-Endos 
activity (Figure 3); as expected from previous studies (74), RNAi for fly PP2A-A destabilizes 
PP2A-C, and vice versa.  In contrast, RNAi for PP1-87B, whose product accounts for more 
than 80% of the PP1 activity in Drosophila larvae (17), only slightly decreased anti-Endos 
(Figure 3).  dsRNAs against coding sequences for all other PPP family catalytic subunits (PP4, 
PP5, and PP6) had no obvious effects on anti-Endos levels (data not shown). 
Analogous experiments to deplete phosphatase catalytic subunits from HeLa cells using 
siRNAs were clearly successful only in the case of PP4, where no effects on either anti-Endos 
or anti-CDKS activities were observed (Figure 3 – figure supplement 1A,B).  Mouse MEF 
cells homozygous for a knock-out allele of the PP5 gene (94) also displayed the same levels of 
anti-Endos and anti-CDKS activities as control cells (Figure 3 – figure supplement 1C,D).  
These knockdown/mutation experiments argue strongly that the predominant anti-
Endos phosphatase is some form of PP2A.  Most PP2A activity in vivo is ascribed to 
heterotrimeric enzymes containing the C and A subunits plus one of several kinds of regulatory 
B subunits (35).  To distinguish which form of PP2A is anti-Endos, we took advantage of the 
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fact that the Drosophila genome has a near-minimal set of genes encoding PP2A regulatory 
subunits (for example, one B55-type subunit as opposed to four in mammals; and two B56-
class  (B’)  subunits  versus  five  in  mammals).  Null or strongly hypomorphic mutations are 
available for almost all of these fly genes (11, 27, 52, 83, 84); animals homozygous for these 
mutations usually survive until third instar larval or pupal stages because maternal 
contributions are sufficient for earlier stages of development (21).   
Extracts prepared from mutant third instar larvae were assayed for anti-Endos and anti-
CDKS activities, as well as phosphatase activity against Histone H1v1.0 as an additional 
control.  The results were striking and unanticipated: Relative to wild-type, larvae homozygous 
for mutations in twins (the gene encoding the sole B55-type subunit in flies) were not only 
deficient in anti-CDKS as expected, but they also lacked anti-Endos; the same was true for 
brains isolated from these larvae (Figure 4A).  Activities against Histone H1v1.0 were 
virtually unaffected in twins mutants.  On Western blots, the twins larvae had no detectable 
Twins (B55) protein; moreover, gross levels of PP2A-A and PP2A-C were not diminished by 
the absence of Twins (Figure 4B).  None of these phosphatase activities were altered in larvae 
carrying mutations in genes for any other tested PP2A regulatory subunit, for the PPP4R3 
regulatory subunit of PP4 (flfl), or for any of the PP1 catalytic subunits (with the possible 
exception of a decrease in Histone H1v1.0 dephosphorylation in PP1-87B larvae; Figure 4A). 
 
The predominant anti-Endos activity co-purifies with the PP2A-B55 heterotrimer 
As just seen, depletion/mutation of any of the three components of the PP2A-B55 
heterotrimer removes the large majority of the phosphatase activity directed against the Gwl 
site in pEndos.  These findings were very surprising, given that PP2A-B55’s  action  against  
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CDK-phosphorylated substrates differs in many properties from anti-Endos, and the sequence 
motifs phosphorylated by Gwl and CDKs are very different.  We were thus concerned that the 
effects of PP2A-B55 depletion on pEndos dephosphorylation could be indirect: That is, PP2A-
B55 might not be anti-Endos, but its loss might instead disrupt another phosphatase that does 
play such a role.   
To address whether anti-Endos is indeed a PP2A-B55 heterotrimer, we fractionated 
asynchronous HeLa cell extracts by Mono-Q chromatography (Figure 5).  Assays of the 
fractions revealed that anti-Endos and anti-CDKS activities co-purified.  The peak activities 
towards both substrates coincided with the fractions containing the three components of PP2A-
B55 (the A, B55, and C subunits), although the PP1 catalytic subunit was also found in these 
same fractions.  PP5 and PP6 elute from the Mono-Q column at much lower salt concentrations, 
while PP4 and the B56 and  B’’’  (striatin)  regulatory subunits of PP2A elute at higher salt than 
the peak anti-Endos/anti-CDKS (Figure 5).  The anti-Endos activity in the peak fractions has 
the same characteristics as in concentrated extracts: It is sensitive to okadaic acid and fostriecin, 
but insensitive to tautomycetin and phosphomimetic Drosophila Endos (data not shown).  The 
fractionation results are consistent with the idea that anti-Endos is indeed the PP2A-B55 
heterotrimer and further exclude most other PPP enzymes as candidates. 
We next purified recombinant PP2A-B55 heterotrimer from lysates of human 
embryonic kidney (HEK) cells transfected with constructs expressing FLAG-tagged B55 or 
B55 isoforms, or the B56 isoform as a control [as described in (1)].  On silver stained SDS-
PAGE gels, the FLAG immune complexes showed predominant bands at the positions of the A, 
FLAG-B55 or FLAG-B56, and C subunits of PP2A (Figure 6 – figure supplement 1).  Some 
variable contaminating bands were also seen in control immune complexes isolated from 
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lysates of cells transfected with empty vectors.  Mass spectrometry identified these proteins as 
keratins or immunoglobulin chains (from the antibody on the FLAG affinity beads) unlikely to 
contribute to phosphatase activities.   
Heterotrimers containing B55 and B55 isoforms efficiently dephosphorylated 
pEndos and CDKS substrates (Figure 6A).  Pilot experiments allowed us to choose 
concentrations of the enzymes and time of reactions in which subsequent investigations could 
be performed in the linear range for these variables (Figure 6 – figure supplement 2).  Neither 
control PP2A-B56 heterotrimers nor empty vector preparations made in parallel displayed 
any activity against either substrate.  Neither the anti-Endos nor anti-CDKS functions of the 
PP2A-B55 preparations could be attributed to heterotrimer dissociation into A-C dimers, 
because purified dimer does not target either substrate even when in 10-fold excess relative to 
the heterotrimeric holoenzymes (Figure 6A).  The anti-Endos and anti-CDKS activities of the 
PP2A-B55 heterotrimer were similarly sensitive to fostriecin, as expected if the catalytic 
subunit is the same (Figure 6B).  However, the anti-Endos activity of PP2A-B55 was much 
less sensitive to either tautomycetin or phosphomimetic Endos than was the anti-CDKS 
activity of the same preparations (Figure 6C,D), as was also true for unfractionated extracts 
(review Figure 2D,E) and the peak Mono-Q fractions (data not shown). 
 
pEndos is a tight-binding but slowly-dephosphorylated substrate of the PP2A-B55 
heterotrimer  
To understand the different properties of PP2A-B55 with respect to pEndos and CDK-
phosphorylated substrates, we performed kinetic analyses of phosphatase activities using 
purified components and analyzed the data using the Michaelis-Menten reaction scheme 
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allowing for tight-binding (see Materials and Methods).  The results are summarized in Table 1; 
the data on which these results were based are presented in Figure 7.  Measurements of 
nanomolar or subnanomolar Km values for the dephosphorylation of pEndos by traditional plots 
of initial reaction rates as a function of the substrate concentration are technically challenging 
because of the very low concentrations of enzyme and substrate involved; these issues could 
lead to overestimates of the Km. We therefore supplemented these studies (Figure 7A-C) with a 
more accurate alternative approach based upon competition between pEndos and okadaic acid 
for access to the enzyme’s  active  site  (see  Materials  and  Methods  and  Figure 7D,E).   
The data summarized in Table 1 indicate that the kcat for the dephosphorylation of 
pEndos by PP2A-B55 is two to three orders of magnitude slower than that for the reaction of 
the same enzyme with CDKS substrate, while the Km values for the two substrates differ by 
more than four and perhaps even five orders of magnitude.  Table 1 presents the results as a 
range of values representing multiple experiments with several independent preparations of 
PP2A-B55 and either pEndos or pCDKS.  We believe the actual kcat for the pEndos reaction is 
likely to lie in the higher end of its range, because some measurements were taken with older 
preparations of enzyme that had lost some activity.  We further anticipate that the actual Km for 
this same reaction is in the lower end of its range, because we obtained lower values using 
hexahistidine tagged pEndos than with a pEndos substrate containing a bulkier tag (maltose 
binding protein) that might have slightly impaired the interaction.  [To appreciate the 
difficulties inherent in these measurements, it is informative to consider that, of more than 
6200 enzymatic reactions currently cataloged in the BRENDA enzyme database 
[http://www.brenda-enzymes.org; see (73)], only three have Km values less than 10 nM and 
none has a subnanomolar Km.]  In any event, the differences between the reactions using 
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pEndos or pCDKS substrates are so pronounced that any variations within the ranges shown in 
Table 1 are ultimately inconsequential to the models presented below. 
These unusual kinetic properties explain the apparent paradox that a single enzyme, 
PP2A-B55, exhibits both anti-CDKS and anti-Endos activities that differ markedly in their 
responses to inhibition by both tautomycetin/tautomycin and an Endos phosphomimetic protein 
and to the dilution of extracts.  In each case, the discrepancy is explained by careful 
quantitative attention to the relationship between the Ki of the inhibitor and the Km of the target: 
Roughly speaking, an inhibitor will be effective only if its Ki  is less than the Km for the 
substrate.  Thus, as was seen in Figure 6C, tautomycetin, which has an IC50 (which provides 
an very rough estimate of Ki ) of 62 nM (53), effectively inhibits PP2A-B55 dephosphorylation 
of CDKS (Km ~ 90 M, Table 1), but only weakly inhibits PP2A-B55 dephosphorylation of 
Endos (Km ~ 1 nM, table 1).  The same consideration explains the difference in inhibition by 
the Drosophila S68 Endos phosphomimetic protein, whose IC50 (approximately 500 nM from 
Figure 6D) is again intermediate between that for dephosphorylation of pEndos and pCDKS.  
Although the identity of the inhibitor(s) present in extracts that presumably underlie the 
dilution effects seen in Figure 2F are unknown, the different sensitivities of anti-Endos and 
anti-CDK to extract dilution can be rationalized if the inhibitors’ Ki values are in the range of 1 
nM – 90 M, i.e., intermediate between the Km’s  of  pEndos and pCDKS.  
 
pEndos inhibition of PP2A-B55 depends on competition at the active site 
Two findings clearly indicate that pEndos interacts with the active site of PP2A-B55.  
First, pEndos is a substrate that is dephosphorylated by this enzyme at a measurable rate; and 
second, pEndos  competes  with  okadaic  acid,  a  drug  known  to  bind  only  to  PP2A’s  active  site 
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(93).  Our results provide no indication that pEndos inhibits PP2A-B55 by binding to a second, 
allosteric site separate from the active site at which it is dephosphorylated.  Such allosteric 
down-regulation would cause the rate of pEndos dephosphorylation to decrease when the 
substrate is added at very high concentrations, but this is not the case (Figure 7B).  
Furthermore, the different responses of purified PP2A-B55’s  anti  Endos  and  anti-CDKS 
activities to the addition of phosphomimetic Drosophila Endos (S68D in Figure 6D) also argue 
strongly against inhibition at an allosteric site.  If pEndos inhibited PP2A-B55 by binding to a 
site other than the active site, phosphomimetic Endos would have been expected to inhibit the 
dephosphorylations of pEndos and pCDKS at identical concentrations, and this is clearly not 
the case. 
Figure 8A provides yet another demonstration that the ability of pEndos to inhibit 
PP2A-B55  is  mostly  dependent  on  interactions  at  the  enzyme’s  active  site.    We  assayed  the  
response of PP2A-B55’s  anti-CDKS activity to increasing concentrations of either 
unphosphorylated Endos or Endos previously thiophosphorylated by Gwl kinase; the 
incorporated thiophosphate cannot be removed by this enzyme [(58) and data not shown].  The 
IC50 of thiophosphorylated Endos determined in this way was 197 ± 14 pM; by comparison, 
the IC50 of nonphosphorylated Endos was measured to be 566 ± 65 nM.  Thus, the 
(thio)phosphorylation of Endos increases its binding affinity for PP2A-B55 about 3000-fold.  
Although these data do not preclude the existence of interactions outside of the active site and 
involving regions of Endos distant from the Gwl-phosphorylated site, it is clear that most of the 
binding is dictated by insertion of the phosphorylated residue into the active site, where it can 
then be dephosphorylated.  Indicative of the strong affinity between activated Endos and 
PP2A-B55, the IC50 of thiophosphorylated Endos is only about twice that of okadaic acid 
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measured in similar assays [107 ± 10 pM (Figure 8A), in close accordance with previous 
determinations (14, 36, 87)].   
These results suggest that Gwl-phosphorylated pEndos inhibits the dephosphorylation 
of CDK-phosphorylated substrates through competition for PP2A-B55’s  active  site  (Figure 9).  
We call our model for this mechanism inhibition by unfair competition to reflect the large 
disparities between the kinetic parameters for pEndos in comparison with other substrates.  
pEndos binds rapidly to all available PP2A-B55, while the release of Endos from the enzyme 
(either through dissociation or the removal of dephosphorylated Endos product) is very slow.  
Sequestration by pEndos would thus severely compromise the ability of PP2A-B55 to target 
alternative substrates with much higher Km values (in the 1 range or above).  
 
PP2A-B55 can reactivate itself by dephosphorylating pEndos 
One prediction of the inhibition by unfair competition hypothesis is that PP2A-B55 
should be able to auto-reactivate at the conclusion of M phase.  By dephosphorylating pEndos 
inhibitor that can no longer be replenished once Gwl is inactivated, PP2A-B55 is now freed to 
recognize its normal, CDK-phosphorylated substrates.  We tested this idea by setting up an in 
vitro analog of this aspect of M phase exit.  We added varying amounts of non-radioactive 
pEndos to PP2A-B55,  and  monitored  the  enzyme’s  ability  to dephosphorylate radioactive 
pCDKS added at the same time.  The results, shown in Figure 8A, show clearly that pEndos 
indeed inhibits PP2A-B55-mediated CDKS dephosphorylation.  Much higher concentrations of 
pEndos than thiophosphorylated Endos are needed to achieve the same degree of inhibition, 
which is to be expected if pEndos is being inactivated during the incubation.  As the time of 
incubation increases, PP2A-B55 consumes more pEndos, so even higher concentrations of 
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pEndos are required for the same amount of inhibition.  Comparing the effects of pEndos 
inhibition after 30 and 120 minute incubations demonstrates that PP2A-B55 cannot recognize 
the pCDKS substrate until the majority of the pEndos in the same tube has been 
dephosphorylated.  We estimate that the kcat for the dephosphorylation of pEndos in these 
reactions is between 0.03 and 0.12 sec-1, consistent with the range previously determined in 
Table 1. 
Figure 8B provides straightforward evidence for the automatic reset of PP2A-B55 
activity that we postulate occurs after the enzyme has succeeded in inactivating pEndos.  At the 
beginning of this experiment, purified PP2A-B55 was mixed on ice with either buffer, 
nonradioactive pEndos, or nonradioactive thiophosphorylated Endos; then radioactive pCDKS 
substrate was added and the samples incubated at 30°C starting at t=0.  The time courses of 
pCDKS dephosphorylation, assayed by 32P release, were then measured.  A clear delay in 
pCDKS dephosphorylation of roughly 35 min is visible in the sample containing pEndos, after 
which the rate of the reaction approaches the initial rate observed in the absence of Endos 
inhibitors.  (This delay is longer than would occur in cells because the ratio of pEndos to the 
enzyme is much higher than the physiological condition. Also, even stronger in vivo inhibition 
is predicted because the physiological pEndos concentration is many times higher than the 
concentration used here, which was limited by experimental constraints.) The best-fit values to 
these data, Km = 0.47 ± 0.14 nM and kcat = 0.03 sec-1, are consistent with those determined by 
the okadaic acid competition experiments (Table 1; see Materials and Methods for the 
calculations underlying the theoretical curves). 
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DISCUSSION 
 
PP2A-B55 is the predominant phosphatase targeting the Gwl phosphosite in Endos 
Three independent lines of evidence indicate that the major activity contributing to the 
dephosphorylation of Gwl-phosphorylated Endos is a phosphatase that includes the three 
subunits of the PP2A-B55 heterotrimer.  (1) Inhibitor specificities: All of the anti-Endos 
activity (whether in M phase or interphase) is sensitive to okadaic acid and calyculin A (Figure 
2B and Figure 2 – figure supplement 1), and the majority is highly sensitive to fostriecin 
(Figure 2C and Figure 2 – figure supplement 2), suggesting that the catalytic subunit of the 
anti-Endos phosphatase is PP2A or its less abundant relatives PP4 or PP6.  Furthermore, the 
facts that tautomycetin and the S68D Drosophila phosphomimetic Endos protein are such weak 
inhibitors of anti-Endos (Figure 2 and Figure 6) can be most easily explained if the anti-Endos 
phosphatase has a very low Km for pEndos – below that for either inhibitor – as is the case for 
PP2A-B55.   (2) Ablation of phosphatase activities: Depletion of PP2A-A or -C from S2 tissue 
culture cells removes most anti-Endos from extracts (Figure 3), while depletion of PP4 from 
HeLa cells does not affect this activity (Figure 3 – figure supplement 1).  Drosophila larvae 
mutant for twins, which encodes the sole B55-type regulatory subunit of PP2A in flies, exhibit 
very little anti-Endos, while mutations in genes for other PPP family catalytic and regulatory 
subunits do not impede pEndos dephosphorylation in larval extracts (Figure 4).  (3) 
Biochemical purification of the activity: Anti-Endos copurifies with the anti-CDKS activity 
previously ascribed to PP2A-B55 heterotrimer (9, 55)], while on the same column it resolves 
away from other PPP phosphatase subunits (Figure 5).  Furthermore, highly purified PP2A-
B55 heterotrimer displays robust anti-Endos activity whose properties match that of the 
predominant anti-Endos activity in extracts (Figure 6). 
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Because most of our experiments in Figure 2 were performed with extracts prepared 
from unsynchronous cells (the large majority of which are in interphase), it is conceivable that 
a phosphatase other than PP2A-B55, that is activated only for a very short period following 
anaphase onset, is the enzyme responsible for dephosphorylating pEndos during M phase exit.  
We believe that this possibility is extremely remote for several reasons.  (i) As discussed below, 
the inhibition by unfair competition mechanism we propose is sufficiently fast to account for 
the observed rapidity of M phase exit.  (ii) The characteristics of the M phase and interphase 
anti-Endos activities measured in Xenopus egg extracts are very similar (Figure 2 – figure 
supplements 1C and 2A); PP2A-B55’s  ability  to  dephosphorylate  pEndos  is  therefore 
constitutive with respect to the cell cycle (see also Figure 2A).  (iii)  Because of its extremely 
low Km, pEndos is so tightly bound to PP2A-B55 during M phase that no other hypothetical 
phosphatase would be able to inactivate it in a reasonable time frame; the theoretical 
simulation in Figure 10 below illustrates this point.  We thus see no reason to postulate the 
existence of such a transiently activated phosphatase, and we think this possibility is 
incompatible with the observed relationship between PP2A-B55 and pEndos. 
Some extracts contain a secondary activity (~10-30% of the total) that also targets the 
Gwl site in Endos.  We have not characterized this minor activity in detail, but some evidence 
suggests that it may be a form of PP1: It is relatively resistant to fostriecin (Figure 2 – figure 
supplement 2), and RNAi depletion of PP1-87B, the most abundant form of the PP1 catalytic 
subunit, removes ~20-25% of anti-Endos activity from Drosophila S2 cell extracts (Figure 3).   
Regardless of its exact composition, we believe this secondary activity is not very 
important to the ultimate goal of regulating PP2A-B55 function.  Figure 10 – figure 
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supplement 1 models the scenario that another phosphatase (called PPX in the figure, but 
presumptively PP1) exists that can target pEndos.  We chose the Km and kcat values for this 
putative reaction to match those for the dephosphorylation of pCDKS by PP2A-B55 (from 
Table 1), and the concentration of PPX to be the same as that of PP2A-B55 (about 100-250 nM 
by our estimation, depending on cell type), but in fact the basic conclusions would be 
essentially unaltered by 10-fold changes in any of these assumptions.  At high pEndos 
concentrations above the intracellular concentration of PP2A-B55, PPX could dephosphorylate 
the excess pEndos that was not bound to PP2A-B55.  However, this dephosphorylation would 
have little regulatory consequence: As soon as the pEndos concentration is reduced to the 
intracellular concentration of PP2A-B55, the remaining pEndos would be protected from 
dephosphorylation by PPX due to the very tight (nanomolar or subnanomolar) binding of 
pEndos to PP2A-B55.  The consequences of this conclusion to the dynamics of the M phase-
to-interphase transition will be further explored later in the Discussion.    
Since the original submission of this manuscript, three other papers have been 
published whose results bear on our identification of PP2A-B55 as the major anti-Endos 
phosphatase.  The results from two of these studies support this conclusion.  First, S. Mochida 
measured the IC50 of pEndos and thiophosphorylated Endos and obtained values very close to 
those shown in our Figure 8A (54). Moreover, he demonstrated that Endos bound by PP2A-
B55 is in close proximity to both the B55 and C (catalytic) subunits of the enzyme, consistent 
with a location at the active site.  An extremely tight association of phosphorylated Endos with 
the PP2A-B55 active site is an essential feature of our inhibition by unfair competition model.  
Second, during the course of an investigation that will be discussed further below, the 
laboratory of F. A. Barr provisionally identified PP2A-B55 as the phosphatase responsible for 
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dephosphorylating pEndos in a mammalian cell system (15). 
 
Fcp1 is not a major anti-Endos phosphatase 
 A third recent publication (30) came to a conclusion incompatible with that presented 
here: These authors maintain that the anti-Endos enzyme is Fcp1, a phosphatase known to 
target phosphorylations of the C-terminal domain (CTD) of RNA polymerase II.  We believe 
their report is incorrect for several reasons.  (i) We show here strong evidence that PP2A-B55 
is responsible for the anti-Endos activity.  Furthermore, Figure 10C,D demonstrates that given 
the very tight binding of pEndos to the PP2A-B55 active site blocks its binding to other 
phosphatases. No other normal-binding phosphatase could contribute to pEndos inactivation 
rapidly enough to account for the timing of M phase exit.  (ii) Among other issues, this new 
publication is internally inconsistent.  The authors show that the anti-Endos activity they 
ascribe to Fcp1 is okadaic acid sensitive [supplemental Figure S3 in reference (30)], yet the 
literature contains many reports that Fcp1 is completely resistant to okadaic acid [e.g., (44, 64, 
85, 89)], a fact that we verify in our Figure 11E. 
 We have also obtained results that more directly exclude Fcp1 as a major anti-Endos 
phosphatase.  (iii) In mono-Q chromatography, Fcp1 does not co-fractionate with the pEndos-
dephosphorylating activity.  Figure 5 shows that fractions with peak anti-Endos activity (such 
as fractions from 37 to 39) have no detectable Fcp1 protein.  (iv) RNAi depletion of more than 
90% of the Fcp1 in Drosophila S2 cells has no obvious effect on the ability of extracts made 
from these cells to dephosphorylate pEndos (Figure 11A,B).  (v) Purified S. pombe Fcp1 
enzyme has detectable anti-Endos activity, but this is very low.  At a physiological 
concentration of the pEndos  (1 M), each molecule of Fcp1 has less than 1/1,000th the 
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efficiency of a molecule of PP2A-B55 in dephosphorylating this substrate (Figure 11C,D).  
Moreover, cells contain more than 10 times more PP2A-B55 than Fcp1 molecules [based on 
values in the Pax-DB database of protein abundances determined by mass spectrometry; see 
www.pax-db.org and reference (88)].  By this estimate, less than 0.01% of the total anti-Endos 
activity in cells can be ascribed to Fcp1.  It should be cautioned that our measurements of Fcp1 
enzyme kinetics were made using the heterologous S. pombe enzyme, but the structure of Fcp1 
is well conserved in evolution. 
 
A simple competition mechanism explains how pEndos acts both as an inhibitor and a 
substrate for PP2A-B55 
In Figure 9, we propose a straightforward model for the relationship between pEndos 
and PP2A-B55.  In essence, pEndos competes with a large class of CDK-catalyzed mitotic 
phosphosites (of which pCDKS and pSer50 Fizzy are examples) for access to the phosphatase 
active site.  pEndos can successfully compete for the site because its affinity for PP2A-B55 is 
much higher than those of the competing substrates; that is, the Km for pEndos is extremely low.  
However, PP2A-B55 dephosphorylates pEndos at a much slower rate (low kcat) than the CDK 
phosphosites, so the tight interaction of these molecules would be prolonged.  Thus, pEndos 
would soon sequester the phosphatase from competing substrates, protecting such substrates 
against premature dephosphorylation.  pEndos in this way permits M phase to begin and to be 
maintained as long as Gwl kinase is active.  We call this mechanism inhibition by unfair 
competition.  In its essence, the model shown in Figure 9 clarifies how PP2A-B55  can  be  “off”  
during M phase for CDK-phosphorylated  substrates,  but  “on”  at  the  same  time  for  the  Gwl-
phosphorylated pEndos substrate.  
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In the context of the cell, the inhibition by unfair competition mechanism requires that 
pEndos be present in molar excess over PP2A-B55 in mitosis in order to account for the near-
total absence of anti-CDKS activity observed during M phase [(9, 55, 56); see also Figure 2A].  
Considerable evidence exists that this requirement is met in many cell types.  From our own 
quantitation on Western blots, we estimate the intracellular concentration of the PP2A B55 
subunit to be between 100 and 250 nM and that of Endos to be between 500 nM and 1 
depending on the cell type. (One example of this analysis is seen in Figure 2 – figure 
supplement 6The 5:1 ratio of Endos to PP2A-B55 observed in that figure is roughly 
consistent with estimates from other laboratories (15) and with estimates from mass 
spectrometry studies of whole cell extracts, after accounting for all Endos and PP2A-B55 
family members (3, 7, 43, 88).]  For example, the Pax-DB database integrating the results of 
many mass spectrometry experiments on a variety of tissue types estimates that the abundance 
of Endos in Drosophila cells is 295 ppm while that of Twins (B55) is 123 ppm; for human cells, 
the integrated datasets yield values of 83.2 ppm for Endos-family proteins (ENSA and ARPP-
19) and 23.1 ppm for B55-family proteins [see www.pax-db.org and reference (88)].  Although 
we ourselves have not determined the fraction of the total Endos protein that is phosphorylated 
during M phase, other investigators have found that this proportion is roughly 50% in extracts 
of synchronized mammalian tissue culture cells (perhaps some of which may not have been in 
M phase) (15), and approaches 100% in frog egg M phase extracts (57).  Sufficient  “headroom”  
thus exists to conclude that the molar concentration of pEndos during M phase in fact exceeds 
that of the PP2A-B55 phosphatase. 
A major virtue of the inhibition by unfair competition model is that it explains not only 
how pEndos inhibits PP2A-B55 dephosphorylation of pCDKS-class substrates, but also how 
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pEndos can itself become inactivated:  The system has an automatic reset that is intrinsic to the 
mechanism that inactivates PP2A-B55 phosphatase in the first place.  When Gwl is inactivated 
at anaphase onset, the pEndos dephosphorylated by PP2A-B55 can no longer be replaced.  
PP2A-B55 is now free to work on CDK-phosphorylated substrates and thus to promote the M-
to-interphase transition.  The experiments presented in Figure 8, in which we added non-
radioactive pEndos and radioactive pCDKS to the same tube of PP2A-B55, provide a direct in 
vitro test of the proposed mechanism by mimicking the events that occur during M phase exit.  
The results show that PP2A-B55 targets pCDKS only after the enzyme has dephosphorylated 
almost all of the pEndos. 
Rapid M phase exit requires the inhibition by unfair competition mechanism 
M phase exit is surprisingly rapid given the large number of phosphorylations which 
must be reversed; in Xenopus cycling extracts, for example, the M phase-to-interphase 
transition is completed within less than 5 minutes (56, 97).  Even though the turnover rate of 
pEndos dephosphorylation by PP2A-B55 is quite slow (~0.05 sec-1), the inhibition by unfair 
competition mechanism is nevertheless compatible with the rapidity of M phase exit.  The 
reason is that Endos is present in cells only in at most a 5-fold stoichiometric excess with 
respect to the phosphatase, as was just discussed.  Each molecule of PP2A-B55 thus needs to 
dephosphorylate only a few molecules of pEndos to effect the M-to-interphase transition.   
To explore this idea quantitatively, we modeled the dynamics of a simplified system 
consisting solely of Endos and PP2A-B55 at estimated physiological conditions (Figure 10A).  
Because the Km of PP2A-B55 for pEndos is four-to-five orders of magnitude smaller than the 
Km for other substrates, typified by pCDKS (Table 1), and the pEndos concentration during M 
phase is in excess of the phosphatase concentration, we suggest that the approximation of 
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ignoring the binding of PP2A-B55 to other substrates is appropriate, and that this simplified 
model should capture the essence of the regulatory process.  The calculation begins at the end 
of M-phase (t=0) with the inactivation of Gwl.  Almost all the PP2A-B55 is sequestered by 
pEndos until PP2A-B55-catalyzed dephosphorylation causes the pEndos concentration to 
decrease from 1 M to ~250 nM, the intracellular PP2A-B55 concentration.  Beyond this point, 
PP2A-B55 is rapidly released from sequestration; half is available to act on other substrates 
within 74 seconds (Figure 10A).  Note that this calculation essentially recapitulates the actual 
experiments shown in Figure 8, but here the inhibition of PP22A-B55 is stronger and the time 
to release is faster because physiological, not laboratory, conditions are being modeled.  
We previously showed in Figure 2 – figure supplement 2 that cells likely harbor a 
pEndos-targeting phosphatase other than PP2A-B55; because this secondary activity is 
fostriecin-resistant, we speculate that it may be a form of PP1.  Figure 10B shows how the 
time courses of pEndos dephosphorylation and PP2A-B55 desequestration are modified if this 
second phosphatase (again called PPX) is present at the same concentration as PP2A-B55 and 
acts on pEndos with kinetic parameters matching the activity of PP2A-B55 on pCDKS.  In this 
case, the lag in PP2A-B55 desequestration shown in Figure 10B is shortened, because PPX 
can dephosphorylate the pEndos that is not bound to PP2A/B55.  However, as illustrated in 
Figure 10 – figure supplement 1, the presence of PPX makes very little difference once the 
pEndos concentration decreases to the PP2A-B55 concentration of 250 nM, since almost all the 
remaining pEndos is bound to PP2A-B55.  Half the PPA-B55 is released from pEndos by 38 
seconds, producing a modest acceleration in M phase exit.  We regard the situation shown in 
Figure 10B as a reasonable description of the actual events in the cell, as it accounts for 
contributions from both PP2A-B55 and other phosphatases in pEndos inactivation.   
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Further dynamic modeling surprisingly revealed a key insight: Cells would be unable 
to exit M phase in a timely manner unless pEndos was in fact dephosphorylated by PP2A-B55 
as demanded by unfair competition.  Figure 10 C,D assumes that pEndos is only an inhibitor 
and not a substrate of PP2A-B55; thus pEndos binds and sequesters PP2A-B55, but is only 
dephosphorylated by PPX (whose concentrations and properties are identical to those in 
Figure 10B).  In this scenario, PP2A-B55 would protect the bound pEndos from 
dephosphorylation, so many hours – not just a few minutes - would be required for PP2A-B55 
desequestration and M phase exit.  In other words, the dephosphorylation of pEndos by PP2A-
B55 is an absolute requirement for rapid completion of the M phase-to-interphase transition. 
Our identification of PP2A-B55 as the anti-Endos phosphatase poses a dilemma in 
terms of M phase exit: The inhibition by unfair competition model describes events that must 
occur downstream of the inactivation of Gwl kinase, but what then can inactivate Gwl upon 
anaphase onset?  According to our model, the rate-limiting Gwl-inactivating phosphatase 
cannot be PP2A-B55, because the system would be futile.  Gwl inactivation could not proceed 
until pEndos was depleted, but pEndos cannot be inactivated as long as Gwl is active.  An 
argument can be made that PP2A-B55 should be the Gwl-inactivating phosphatase because 
Gwl is activated by CDKs (5), and PP2A-B55 targets at least a subset of CDK phosphosites (9, 
55, 56).  Indeed, one group has recently reported some evidence in favor of this idea (30).  
However, it should be emphasized that PP2A-B55 does not act on all, or even perhaps the 
majority, of CDK phosphosites, as recently most forcefully demonstrated by Cundell et al. 
(15).  The obvious resolution of this dilemma is therefore that a phosphatase other than PP2A-
B55 inactivates Gwl during M phase exit.  We have obtained preliminary evidence in support 
of this idea in two ways (data not shown).  First, in our hands purified PP2A-B55 in vitro is 
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very inefficient in inactivating Gwl.  Second, when active Gwl is added to interphase extracts 
from a variety of cell types, it becomes rapidly inactivated and dephosphorylated in a process 
that is insensitive to okadaic acid (and cannot therefore be controlled by PP2A-B55).  Some 
evidence in favor of the existence of an okadaic acid-resistant anti-Gwl phosphatase has also 
recently been obtained by another group (30); the identity of this Gwl-inactivating enzyme is 
currently unknown. 
F. A. Barr and colleagues have recently proposed an elegant model in which the events 
of anaphase onset are ordered in time, with later events such as cytokinesis being controlled 
by the Gwl-Endos pathway (15).  Our conclusions are in essence consistent with their 
hypothesis, and the automatic reset mechanism we propose provides an explanation for part of 
the delay they observe between CDK1-Cyclin B inactivation and the activation of PP2A-B55, 
and thus for the dephosphorylation of late substrates involved in cytokinesis such as PRC1.  
That is, the major determining factors for this delay would be the rate of Endos 
dephosphorylation by PP2A-B55 described here coupled with the time required to inactivate 
Gwl through mechanisms we do not yet understand. 
 
Other AGC kinases may indirectly inhibit other PPP phosphatases through similar 
mechanisms 
The virtues of inhibition by unfair competition are sufficiently compelling that one 
might ask whether other phosphatases are controlled in the same fashion.  We believe this 
supposition is likely, based on findings published 30 years ago concerning inhibition of PP1 by 
a polypeptide called Inhibitor-1 that is, like Endosulfine, small and heat-stable (19).  Inhibition 
occurs only after Inhibitor-1 is phosphorylated at a conserved site by the cAMP-dependent 
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protein kinase (PKA), an enzyme whose structure and activation mechanism are closely related 
to those of its fellow AGC kinase family member, Gwl (5).  The investigators found that 
purified PP1 could dephosphorylate PKA-phosphorylated Inhibitor-1, and the values of Km and 
kcat were both considerably lower for this reaction than for dephosphorylation of the more 
normal substrate phosphorylase a (19). In short, just as we report here for pEndos and PP2A-
B55, they concluded that pInhibitor-1 acts both as an inhibitor and a substrate for PP1. 
These observations have long since been disregarded because PP1’s  activity  in  
inactivating pInhibitor-1 was very slow, and other phosphatases (PP2A and calcineurin) had 
substantial pInhibitor-1 dephosphorylating activity (13, 34).  In light of the arguments 
summarized in Figure 10 that a phosphatase will effectively sequester a tightly binding 
inhibitor from other phosphatases, we believe the biological significance of PP1’s  activity  in  
dephosphorylating pInhibitor-1 should be re-evaluated.  Of interest, recent studies in Xenopus 
egg extracts have indicated that pInhibitor-1 dephosphorylation at the end of M phase is in fact 
dependent upon activity of PP1, although this work could not distinguish whether the effect 
was direct or indirect (92).  The inhibition by unfair competition mechanism may well prove to 
have been utilized by AGC kinases other than Gwl to control phosphatases other than PP2A-
B55.  
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MATERIALS AND METHODS 
Fly stocks  
Extracts from third instar larvae of the following genotypes were assayed for phosphatase 
activities: PP2A B55 regulatory subunit (twins): twsP/tws196 (39, 83). PP2A B56 regulatory 
subunit type 1 (widerborst): wdb12-1/wdb12-1 (45).  PP2A B56 regulatory subunit type 2 (well-
rounded): wrdKG01108/ wrdKG01108 (70).  PP2A  B’’’ (striatin) regulatory subunit (connector of 
kinase to AP-1): cka05836/ckaS1883 (66, 77).  PP4 regulatory subunit PP4R3 (falafel): 
flflN42/flfl795 (76).  PP1 catalytic subunit (protein phosphatase 1 at 87B): PP1-87B1/PP1-
87B87Bg-3 (22, 69).  PP1 catalytic subunit (protein phosphatase 1 at 96A): PP1-96A2/PP1-
96A2 (41).  PP1 catalytic subunit (flapwing; also known as PP1-9C): flw6/flwGO172 (4, 42, 68). 
Stocks with these mutant alleles were obtained from the Drosophila Stock Center 
(Bloomington, IN) and rebalanced over chromosomes containing Tubby (Tb) to facilitate the 
identification of homozygous or trans-heterozygous mutant third instar larvae.  For the genes 
on the third chromosome (tws, wdb, flfl, PP1-87B, PP1-96A) the balancers used either were 
TM6B, Tb1 AntpHu or TM6C, Tb1 Sb1.  For the cka gene on the second chromosome, the 
balancer was CyO-TbA, while for the flw gene on the X chromosome, the balancer was 
FM7A-TbA (46).  The wrdKG01108 mutation is homozygous viable.  For certain genes, trans-
heterozygous combinations of mutant alleles were employed as indicated by the genotypes 
above to obtain mutant third instar larvae; this was necessary because chromosomes bearing 
the single mutations have over time accumulated second-site lesions causing earlier lethality. 
 
 
Cell lines  
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HeLa CCL-2 and HEK293 CRL-1573 cells were obtained from the American Type Culture 
Collection (Manassas, VA).  PP5 +/+, +/- and -/- mouse MEF cells (94) were the kind gift of 
Dr. Wenian Shou, (Indiana University-Purdue University, Indianapolis, IN).  All mammalian 
cell lines were grown in Dulbecco’s  Modified  Eagle  Medium + 10% Fetal Bovine Serum 
(Invitrogen).  Drosophila S2 cells were grown in Insect-Xpress with L-Glutamine (Lonza 
BioWhittaker; catalog number 12-730Q).  Both mammalian and insect cells were grown in the 
presence of 100 units/ml of penicillin and 100 g/ml of streptomycin and a 1:100 dilution of 
the antimycotic Fungizone (Gibco). 
 
Phosphatase substrates 
Substrates for phosphatase reactions were purified as previously described (9) from E. coli 
transformed with recombinant plasmids constructed from the vector pMAL-C2X (New 
England Biolabs) and expressing maltose binding protein fusions with the following 
peptides/proteins: full-length Xenopus Endosulfine  [Endos; (9, 39)]; the region from Xenopus 
PP1 surrounding the phosphosite Thr311 [we term this substrate CDKS; (9, 55, 56)]; the 
region surrounding the Ser50 phosphosite of Xenopus Fizzy [Fzy; (9, 55, 56)]; amino acids 1-
27 of Drosophila Histone H3; and full-length H. sapiens histone H1.0 (purified Histone H1.0 
protein obtained from New England Biolabs yielded identical results).  In a few experiments 
included in Table 1, Xenopus Endos was cloned into the vector pQE30 (Qiagen) so as to 
express hexahistidine-tagged protein.  Bovine myelin basic protein (MyBP) was from 
Millipore.  Substrates for phosphatase assays of the RNA polymerase II C-terminal domain 
(CTD) were purified as GST-CTD fusions as previously described (78). 
The purified proteins were 32P-phosphorylated in vitro by Gwl kinase (Endos), by 
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CDK1-Cyclin A (CDKS, Fzy Ser50, and Histone H1.0), by Protein Kinase A (New England 
Biolabs; Histone H3 and MyBP), or by mitogen activated kinase 2 (MAPK2; New England 
Biolabs; RNA polymerase II CTD) using methods previously described (9, 78). Proteins were 
purified away from the kinase and other reaction components, and desalted and concentrated 
using Amicon Ultracel 10K centrifugal filter columns and substrate buffer (20 mM Tris, pH 
7.5; 150 mM NaCl).   The incorporation of phosphate was determined to be between 0.5-1.0 
per mole of protein based on measurements of protein concentration and specific activity.   
For some studies, the Endos fusion protein was thiophosphorylated by Gwl in the presence of 
1 mM ATP-[]-35S instead of ATP.   Dephosphorylation of 35S-thio-phosphorylation by 
purified PP2A-B55 was not detectable. 
 
Cell-free extracts 
Xenopus CSF and interphase extracts were prepared as described (9).  HeLa cells were 
extracted in ice-cold phosphatase buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 
0.1 mM EGTA, 0.25% NP-40] according to reference (75), or M-PER mammalian cell lysis 
buffer (Thermo-Fisher Pierce, Rockford, IL) with the same results.  A 1:100 dilution of 
EDTA-free Proteoblock protease inhibitor (Fermentas) was added to both extraction buffers.  
Drosophila whole larvae or larval brains were homogenized with a pestle in phosphatase 
buffer as above, to which was added a 1:100 dilution of phenylmethanesulfonyl fluoride 
(PMSF; Thermo Scientific), a 1:50 dilution of Halt protease inhibitor cocktail (Pierce), and a 
1:100 dilution of a 100 mg/ml stock solution of soybean trypsin inhibitor (AMRESCO catalog 
number M191).   
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Phosphatase assays 
Extracts prepared in phosphate buffer (see the section on cell-free extracts above) or 
purified enzymes appropriately diluted in PP2A reaction buffer (see below) were used for 
each phosphatase assay.  A no-extract control was always included to verify that the substrate 
did not itself contain phosphatase activity.  Unless otherwise noted, radiolabeled substrates 
were added to a final concentration of 5 M in the reactions.  Phosphatase assays were 
stopped with trichloracetic acid (TCA) after a time at which <20% of the substrate was 
dephosphorylated.  The supernatant was mixed with ammonium molybdate and extracted with 
heptane-isobutyl alcohol according to Mochida and Hunt (55) and the 32P measured in a 
scintillation counter.    
In certain experiments, the following phosphatase inhibitors were used after being 
dissolved in dimethyl sulfoxide (DMSO): fostriecin, tautomycin, and tautomycetin (all from 
Santa Cruz Biochemicals, Dallas, TX), and okadaic acid (LC Labs, Boston, MA).  The 
phosphomimetic Drosophila S68D Endos protein has been previously described (39).  
Inhibitors were pre-incubated on ice with extracts for 10 min prior to addition of the substrate.   
 
RNA interference 
siRNA oligonucleotides (Thermo Scientific) for PP1, PP2A ( and  isoforms), PP4, PP5 and 
PP6 catalytic subunits were transfected into HeLa cells using Dharmafect following the 
manufacturer’s  protocols  (Dharmacon) and harvested after 72 hrs.  The cells were lysed in 
phosphatase buffer and the lysates used to determine activity against 32P-labelled substrates in 
a phosphatase assay as described above, and for knockdown efficiency by Western blotting 
using the antibodies listed below. 
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 The technique used to effect RNAi in Drosophila S2 tissue culture cells has been 
described previously (91).  dsRNA was produced from cDNA clones for the given 
phosphatase subunit by PCR amplification using primers containing a T7 RNA polymerase 
promoter  site  at  the  5’  end.    The primer pair used for the catalytic subunit of PP2A 
(microtubule star) was: 
5’  TAATACGACTCACTATAGGGAGACCTACGCAGCTTACATTTACACATA 3’  and 
5’  TAATACGACTCACTATAGGGAGATAGGTTCGATTGGATTGTATCATTT 3’. 
 
For the A subunit of PP2A (PP2A-29B): 
5’  TAATACGACTCACTATAGGGAGACAGAGTTTGCCATGTACTTGATTC  3’  and 
 5’  TAATACGACTCACTATAGGGAGAGGAATCAAATCGGACTTCAGATACT  3’. 
 
For the major catalytic subunit of PP1 (PP1-87B): 
5’  TAATACGACTCACTATAGGGAGAACCACGAGCAGTCTTTTTCTATCTA  3’  and 
5’  TAATACGACTCACTATAGGGAGAGTG  GCTTTTAATCATGGTATTTGTC  3’. 
 
RNAi depletion of Fcp1 from S2 tissue culture cells has been previously described (20).  In all 
cases, S2 cell pellets were lysed and analyzed as just described for HeLa cells.   
 
Mono-Q chromatography 
Fractionation of HeLa cell lysates by Mono-Q chromatography was performed using 
modifications of published protocols (10, 25).  HeLa cells were lysed in buffer containing 50 
mM Tris-HCl, pH 7.4; 100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.25% NP-40; and 10% 
glycerol.  Cell lysate was then diluted to 20 ml with Buffer A (25 mM Tris-HCl, pH 7.4; 150 
mM NaCl; 1mM DTT; and 10% glycerol).  Diluted lysate was loaded onto a 5 ml HiTrap Q 
HP column (GE Healthcare) equilibrated with Buffer A at a flow rate of 0.5 ml/min.  The 
column was then washed for with Buffer A for 16 min (0.5 ml/min) followed by elution with a 
linear gradient to 500 mM NaCl over 30 min, and the column was then subjected to an 
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additional 30 min wash at 500 mM NaCl.  0.5 ml fractions were collected every minute.  The 
fractions were split into 100 l aliquots, flash frozen in liquid nitrogen, and then stored at -
80°C for later analysis. 
 
Phosphatase purification  
pcDNA5 (vector alone), pcDNA5/FLAG-B55, pcDNA5/FLAG-B55, and pcDNA5/FLAG-
B56 plasmid DNAs were transfected into HEK293 CRL-1573 cells using Lipofectamine 
2000 (Invitrogen) using the manufacturer’s  protocols  and  harvested  after  72  hrs.      PP2A  
trimers were isolated exactly according to Adams and Wadzinski (1).  Protein concentrations 
were measured in comparison to bovine serum albumin (BSA) standards on silver stained gels.  
Western blotting confirmed the identity of the protein bands in PP2A preparations.   
Phosphatase assays with the purified PP2A enzymes were carried out as described above.  
Enzymes were diluted to the appropriate concentration in PP2A reaction buffer (20 mM Tris, 
pH 7.5; 1 mg/ml bovine serum albumin; 0.1% -mercaptoethanol) prior to incubation with the 
substrate being tested. 
 Recombinant Schizosaccharomyces pombe Fcp1 (wildtype and kinase-dead D172N 
mutant) proteins were purified after expression in E. coli cells as previously described (29, 40, 
78). 
 
Western blot analysis and antibodies 
Samples were prepared by mixing equal volumes of the fraction with 2X SDS loading dye, 
followed by boiling for 2 min.  Samples were then resolved on 10% SDS-polyacrylamide gels.  
Proteins were transferred to Immobilon-P membranes (Millipore) as previously described (9).  
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The following primary antibodies were used to probe Western blots (catalog numbers in 
parentheses):  From Abgent: PP6-C (#AP8477b).  From Abnova:  PP4-C (#PAB14146); and 
PP5-C (#H00005536-B01).  From Cell Signaling Technology: PP2A-A (#2309); PP1#2582); 
Twins (PP2A B55 subunit, from clone 100C1; #2290); and FlagTag (DYKDDDDK; #2368).  
From Santa Cruz Biotechnology: PP2A-C, from clone N-25 (#sc-130237); PP1-C, from clone 
E-9 (#sc-7482); and Fcp1 (from clone H300; #sc32867).  From  Stratagene:  PP2A  B’  (B56)  pan  
(#B13009-51).  From Thermo Scientific: -tubulin (#MA5-14992); and  striatin  (PP2A  B’’’;;  
#PA1-46460).  From Upstate/Millipore: PP2A-C subunit, from clone 1D6 (#05-421); and 
PP2A B subunit, from clone 2G9 (#05-592).  Antibodies against the two B56 regulatory 
subunits of PP2A in Drosophila [Widerborst (Wdb) and Well-rounded (Wrd)] were the kind 
gifts of Dr. Timothy Megraw (University of Texas Southwestern Medical Center, Dallas, TX) 
and have been previously described (45).  Antibodies recognizing Drosophila Fcp1 (made in 
rabbits) and TFIIS (made in guinea pigs) were described in (20). 
The secondary antibodies used were: Goat anti-rabbit IgG (H+L)-HRP conjugate (Bio-
rad catalog #170-6515) at a 1:5000 dilution; goat anti-mouse IgG (H+L)-HRP conjugate (Bio-
rad catalog #170-6516) at a 1:3000 dilution; and donkey anti-guinea pig IgG (H+L)-HRP 
conjugate (Jackson ImmunoResearch Laboratories, catalog #706-035-148) at a 1:5000 
dilution.  Chemiluminescent signals were visualized by ECL Western Blotting Substrate 
(Pierce)  according  to  the  manufacturer’s  instructions. 
 
Calculation of Km and kcat from initial reaction rates at varying substrate concentration  
Varying concentrations, [N]T, of 32P-labeled pEndos  (see Figure 7B,C) were incubated 
with [P]T = 0.5 nM PP2A-B55, and the initial velocities, v, of 32P release were measured in 
   36 
(duplicate or quadruplicate) samples in two independent experiments.  Technical limitations 
precluded the use of a PP2A-B55 concentration that was much less than the Km, so the data 
was analyzed using the Michaelis-Menten reaction scheme with equations that accounted for 
tight binding. That is, we did not assume that [N]  [N]T  or that [P]  [P]T. (Unscripted 
variables are unbound concentrations and the T subscript signifies total concentrations.)  
Combining the mass conservation and quasi-steady state equations for the concentration of the 
transient pEndos/PP2A-B55 complex, [NP], gives: 
 
 
 
This quadratic velocity equation has the solution according to reference (59): 
 
. 
The parameters Km and kcat were determined from the data using nonlinear regression assuming 
equal fractional errors (Mathematica Version 9), and the weighted means and standard 
deviations were determined from two independent experiments.  The results are displayed in 
Table 1. 
 
Measurement of Km by competition of pEndos dephosphorylation with okadaic acid 
The measurements described above gave relatively large errors in Km because of the 
difficulty of making measurements at the very low PP2A-B55 and pEndos concentrations 
imposed by the very low Km.  To improve accuracy we used a modification of the approach 
used in (71, 81) to measure the Km by a supplementary method: competing the PP2A-B55-
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catalyzed dephosphorylation of a fixed amount of pEndos with varying concentrations of 
okadaic acid (Figure 7D,E).  This approach was feasible because the dissociation constant of 
okadaic acid with respect to PP2A has been carefully determined (71, 80, 81) and because the 
affinity of pEndos for PP2A-B55 is in the same order of magnitude.  By using an initial 
pEndos concentration  ( [N]T(0) = 50 nM or 1 M, depending on the experiment) that was 
much greater than the PP2A-B55 concentration ( [P]T = 0.25 nM or 1 nM) and by limiting the 
incubation time, we ensured that only a small fraction of pEndos was dephosphorylated, 
facilitating a more accurate determination of the Km.  Moreover, this ensured that [P]T/{[N]T(0) 
+ Km} < 0.005 <<  1, so the total quasi-steady state approximation that was usedor 
mathematical analysis was good (6).  
Mathematical model:  Since okadaic acid and pEndos bind competitively to the active site of 
PP2A-B55, combining the mass conservation equations with the quasi-steady state equations 
determining the amounts of the pEndos/PP2A-B55 and okadaic acid/PP2A-B55 complexes 
we get: 
 
 
 
 
where [N], [O], and [P] are, respectively, the (time-dependent) concentrations of unbound 
pEndos, okadaic acid, and PP2A-B55, the symbols with T subscripts denote the total 
concentrations of these compounds, 𝐾௠ is the pEndos-PP2A-B55 Michaelis constant, and 
𝐾ௗை  (30   ± 2 nM)  is the okadaic acid-PP2A-B55 dissociation constant.  These equations allow 
for tight binding; i.e., we do not assume that [𝑂] ≈ [𝑂]். However, since [𝑁]் ≫ [𝑃]் at all 
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times, the approximation [𝑁] ≈ [𝑁]் is good.  Using this, the equations have the solution 
 
 
 
The rate of pEndos dephosphorylation is determined by the total quasi-steady state equation 
from reference  (6) 
 
 
This equation was numerically integrated using Mathematica Version 9, keeping in mind that 
[𝑁]் and [P] are time-dependent, to determine the total amount of dephosphorylation .  
Experiments were performed to measure the total amount of dephosphorylation  at 
varying values of [𝑂]் and fixed values of [𝑁]், [𝐸]், and t, and weighted nonlinear 
regression was used to estimate 𝐾௠ and 𝑘௖௔௧.  The weighting factors were set assuming that 
the fractional errors in the experimental measurements were identically distributed.  The 
results are displayed in Table 1. 
 
 
Time-dependent inhibition by pEndos of PP2A-B55  dephosphorylation of pCDKS 
 
Figure 8B: Parallel aliquots containing [P]T(0) = 0.25 nM PP2A-B55, [pC]T(0) = 0.47 M 
32P-phosphorylated pCDKS, and either no pEndos, [N]T(0)= 16 nM non-radioactive pEndos, 
or 16 nM thio-pEndos were incubated for the indicated times and the amount of 32P released 
was determined by scintillation counting after removing the pCDKS by TCA precipitation.  
Because the pCDKS concentration was much less than its Km, 71-99 M (Table 1), it bound a 
negligible fraction of PP2A-B55; therefore, the analysis would have been identical to that of 
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Figure 10A except that PP2A-B55 activity decreased continuously, even in the no pEndos 
control, presumably due to degradation or instability. This decrease was modeled assuming a 
constant degradation rate, kdeg, so   d[P]T/dt =  −kdeg [P]T  and  [𝑃]்(𝑡) =    𝑒ି௞೏೐೒௧  [𝑃]்(0).  
The fraction of pCDKS dephosphorylated was small, so we approximated [pC]T(t) = [pC]T(0) 
≡ [pC]T. Therefore, the amount of 32P released from pCDKS in the no-pEndos control was 
 
 
 
where the second line was computed by integrating the first line. An excellent fit was obtained 
using the values determined by nonlinear regression: 𝑘௖௔௧
௣஼஽௄ௌ/𝐾௠
௣஼஽௄ௌ = 0.52   0.01/(M sec) 
and  kdeg  = 0.020  0.001/min.  
The analysis in the presence of pEndos used the quasi-steady-state equations used for 
Figure 10A except that they were modified by the replacement [P]T  [P]T(t) to account for 
the instability of PP2A-B55. [P]T(t) was computed using the value of kdeg as described except 
that the onset of degradation was postponed for 25 min to accord with the data, which shows 
that the PP2A-B55 activity (determined by the slope of the curve) after release from pEndos 
inhibition (e.g., at t ~ 50 min) is greater than that in the no-pEndos control. (This might have 
been due to stabilization of PP2A-B55 by pEndos binding but, in any case, does not 
significantly affect the analysis.)  These equations along with the equation above determining 
𝑑[ 𝑃]  ଷଶ /𝑑𝑡 and the value of 𝑘௖௔௧
௣஼஽௄ௌ/𝐾௠
௣஼஽௄ௌ determined in the no-pEndos experiment were 
numerically integrated to determine [ 𝑃]  ଷଶ (𝑡) as a function of Km and kcat.   These values, Km = 
0.47  0.14 nM and kcat = 0.03    0.0005/sec, were determined by nonlinear regression to the 
data.  
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Theoretical time-course of dephosphorylation of pEndos and activation of PP2A/B55 at 
the end of M-phase.   
Figure 10A:  The values for pEndos PP2A-B55 binding of kon = 0.057/(sec nM) and koff = 
0.0068/sec were determined from the experimentally measured Kd (for thiophosphorylated 
Endos) and kcat.  Since 𝜀 = 𝑘௖௔௧  [𝑃]் {𝑘௢௡(  [𝑁]்(0) + [𝑃]் + 𝐾௠  )ଶ} = 5.6   ×  10ି଻ ≪ 1  ⁄ , 
the total quasi-steady state approximation is expected to be good except for a transient during 
the small time interval 0  t  tc, where 1/{(kon ([N]T(0) + Km)}  0.02 sec [see reference (6)].   
Therefore, we used the total quasi-steady state equations 
 
 
 
 
 
 
These were numerically integrated using Mathematica Version 9 with  [P]T = 250 nM, 𝑘௖௔௧௑  = 
0.05/sec, and 𝐾௠௉= 1.0 nM with the boundary condition  [N]T(0)= 1 M.  
To be certain that the quasi-steady state assumption was valid over the entire time 
course {i.e., including the period when [N](t) < [P](t)}, we recomputed the plots using the 
explicit mass-action equations for d[N]/dt, d[P]/dt, and d[NP]/dt (where NP denotes the 
PP2A-B55/pEndos transient complex). These plots were visually indistinguishable from those 
computed using the quasi-steady state assumption except, as expected, for a brief transient 
during 0  t  tc .   
 
Figure 10B:  We assume that the kinetic constants for the additional phosphatase PPTX are 
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𝐾௠௑ = 85 M and 𝑘௖௔௧௑ = 22.5 sec-1, which are based on the values for PP2A dephosphorylation 
of CDKS (Table 1).  Since 𝐾௠௑ is so large, it is certain that 𝜀 ≪ 1 (see definition above) so the 
total quasi-steady state assumption can again be used. In this case the equations are 
 
 
 
 
 
 
 
 
 
 
where [X] and  [X]T  are the concentrations of unbound and bound phosphatase X, and 
superscripts P and X on the kinetic parameters  kcat and Km identify the relevant enzymes. 
These equations were numerically integrated. 
Figure 10C and D: When PP2A/B55 is assumed to bind, but not dephosphorylate, pEndos 
with dissociation constant 𝐾ௗ௉, the equations are the same with the substitutions 𝐾௠௉   → 𝐾ௗ௉ 
and 𝑘௖௔௧௉   → 0.  These equations were numerically integrated using 𝐾ௗ௉= 0.12 nM, which was 
based on the dissociation constant of the pEndos thiosulfate phosphomimetic (computed from 
the data shown in Figure 8).  
 
 
Fraction of anti-Endos activity coming from PP2A/B55 and PPX 
Figure 10 – figure supplement 1: The first three equations described above for Fig. 10B 
were solved to determine [N], [P], and [X] as functions of [N]0 (using the notation above).  
The amounts of dephosphorylating velocity coming from PP2A/B55 and PPX were then: 
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and the fractional velocities were:  
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Figure 1.  Function of the Gwl  pEndos ⊣ PP2A-B55 module in cell cycle transitions.  
The major driver for transitions between interphase and M phase is the cyclic activation and 
degradation of MPF (Cdk1-CyclinB).  When activated (in part through a feed-forward 
autoregulatory loop involving the kinases Myt1 and Wee1 and the phosphatase Cdc25; not 
shown), MPF phosphorylates many substrates (CDKSs) that play key roles in M phase events.  
One such MPF substrate is the kinase Greatwall (Gwl), which in its active form phosphorylates 
Endosulfine (Endos).  Phosphorylated Endos binds to and inhibits the phosphatase PP2A-B55.  
This inhibition protects MPF substrates, including components of the autoregulatory loop, from 
premature dephosphorylation during M phase entry.  During M phase exit, MPF is inactivated 
by degradation of its Cyclin B component (not shown), and PP2A-B55 becomes reactivated to 
dephosphorylate many MPF substrates.  M phase exit also requires the dephosphorylation and 
inactivation of both Gwl and Endos.  In this report, we show that PP2A-B55 catalyzes Endos 
dephosphorylation.  The activities responsible for the inactivation of Gwl currently remain 
unknown. 
 
Figure 2.  Characterization of anti-Endos in extracts.   In all parts of this figure, red circles 
depict anti-Endos while blue squares represent anti-CDKS.  (A) Anti-Endos is present during 
M phase.  Xenopus CSF (M phase) extracts were incubated at 22°C.  At time t=0, Ca2+ was 
added to half of the extract to induce M phase exit; control extract without Ca2+ remained in M 
phase.   At the indicated times, aliquots were assayed for anti-Endos and anti-CDKS as 
described in Materials and Methods.  During M phase, anti-CDKS (light blue squares) is 
undetectable, while anti-Endos (light red circles) is active.  As the extracts exit M phase 
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[interphase is achieved within 15-20 minutes of Ca2+ addition; (9, 96, 97)], anti-CDKS activity 
(dark blue squares) is strongly induced while anti-Endos (dark red circles) increases about 2-
fold.  (B-E) Drug sensitivities of phosphatase activities.  Y-axis values are the percentage of the 
phosphatase activity for the given combination of extract and substrate measured in the 
absence of the inhibitor.  Anti-Endos and anti-CDKS have similar sensitivities to okadaic acid 
and fostriecin, but anti-Endos is substantially more resistant than anti-CDKS to tautomycetin 
and phosphomimetic Endos S68D.  In B and C, green triangles represent dephosphorylation 
activity against CDK-phosphorylated Histone H3; in C, purple stars are activity against CDK-
phosphorylated Histone H1v1.0.  In part C, the fostriecin resistant portions of the H3 
phosphatase (about 40% of the total) and the H1v1.0 phosphatase (about 80% of the total) 
likely represent PP1 activity.  The HeLa extracts examined in panels B-D were from 
asynchronous cells, the vast majority of which are in interphase.  (F) The specific activities of 
anti-CDKS and anti-H3 increase upon dilution of the extract, presumably because weakly 
binding inhibitors are titrated away, but the specific activity of anti-Endos increases at most 
only marginally upon dilution.  The y-axis shows the phosphatase activity on the indicated 
substrates, normalized to the original volume of undiluted extract.  In all panels, n=1; 
biological and evolutionary replicates of the experiments in panels B-D are presented in Figure 
2 figure supplements 1-5.  
 
Figure 3.  Depletion of PP2A by RNAi disrupts a major component of anti-Endos activity.  
(A)  Phosphatase assays for anti-Endos, anti-CDKS, and anti-Histone H3 activities in mock-
treated control Drosophila S2 tissue culture cells (blue), and S2 cells treated with dsRNAs for 
the PP2A-A subunit (red; the gene is PP2A-29B), the PP2A-C subunit (green; the gene is mts), 
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and the major PP1-C subunit [yellow; the gene is PP1-87B, which accounts for more than 80% 
of PP1-related activity against generic substrates (17)].  Each column represents a separate 
biological replicate (n=4 for the controls and n=2 for each of the three RNAi treatments); 
values were normalized for total protein concentrations in the extracts.  One of the four 
replicates of the control assay was arbitrarily chosen as the 100% reference.  The data indicate 
that a form of PP2A is responsible for about 90% of anti-CDKS, ~70-80% of anti-Endos, and 
~60% of anti-H3; the residual activities are likely due mostly to forms of PP1, although PP5 
may also contribute in the case of anti-H3 (see Figure 4 below).  (B) Western blots showing 
effectiveness of the RNAi treatments.  As reported elsewhere (37), the stabilities of the PP2A-
A and -C subunits are mutually interdependent. 
 
Figure 4.  Drosophila larvae lacking B55 are deficient in anti-Endos.  (A) Extracts were 
prepared from larvae with null or strong loss-of-function alleles of the indicated genes, and 
assayed for anti-Endos, anti-CDKS, and anti-Histone H1v1.0 activities.  Values were 
normalized for the total protein concentrations in the extracts; one replicate of the control assay 
(on a wildtype larva) was arbitrarily chosen as the 100% reference.  Details about the 
genotypes involved are given in Materials and Methods.  The number of biological replicates 
for each genotype is presented inside the corresponding bar, with standard deviations shown.  
Levels of anti-Endos are much lower in twins (encoding the sole B55 subunit in Drosophila) 
larvae than in wild-type (WT) controls (p < 10-20;;  Student’s  two-tailed t-test); this is also the 
case as expected for anti-CDKS (p < 1010).  As a control, phosphatase activity against Histone 
H1v1.10 is relatively unaffected in twins mutant larvae.  Anti-Endos and Anti-CDKS activities 
were also severely compromised in extracts made from brains isolated from twins mutant 
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animals.  No consistent effects were observed in extracts made from larvae mutant for genes 
encoding the other phosphatase subunits indicated, with two exceptions: (1) Extracts from 
larvae mutant for PP1-96A displayed only about half the level of phosphatase activities 
measured with all three substrates.  This is probably a systematic error caused by the ebony 
mutation in these animals, producing a dark pigment that caused an overestimation of the 
amount of total protein concentration.  (2) The lower level of activity against Histone H1v1.0 
in animals mutant for PP1-87B [the predominant PP1 catalytic subunit in Drosophila; (17)] is 
likely caused by the targeting of this substrate by the PP1-87B phosphatase.  (B) Western blots 
of extracts from larvae mutant for genes encoding B55 (twins) and B56 [widerborst (wdb) and 
well-rounded (wrd)] regulatory subunits of PP2A.  The blot at the right verifies that in twins 
mutants, the B55 protein is missing, while the PP2A-A and PP2A-C subunits are present in 
normal amounts. 
 
Figure 5.  Mono-Q chromatography of HeLa extracts.  Total extract from asynchronous 
HeLa cells (high speed supernatant; HS) was applied to the column; FT is the flow-through.  
Proteins were eluted with linear gradient from 150 mM (Fraction 1) to 500 mM (Fraction 75) 
of NaCl.  Individual fractions were assayed (n=1 assay per data point) for anti-Endos (black 
circles) and anti-CDKS (black squares), and were also examined for the indicated phosphatase 
subunits by Western blot.  
 
Figure 6.  Anti-Endos activity of purified PP2A-B55.  (A) PP2A-B55 heterotrimers 
efficiently dephosphorylate Gwl-phosphorylated Endos. Each column represents an individual 
experiment (a biological replicate) in which the indicated enzyme preparations shown in 
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Figure 6 – figure supplement 1 (normalized for the amount of PP2A-C subunit where 
possible, or for the volume of transfected cells in the case of the vector-only control 
preparation) were assayed for anti-Endos activity, anti-CDKS activity, or generic activity 
against myelin basic protein (MyBP) phosphorylated with PKA.  The y-axis indicates the 
percentage of radioactivity in the input substrate that was freed by enzyme treatment.  The 
control preparation had no activity against any of these substrates, while PP2A-B55 and 
PP2A-B55 heterotrimers showed similar strong levels of activity against all three substrates.  
PP2A-B56heterotrimers and PP2A-A/C heterodimers, both of which dephosphorylated the 
generic MyBP substrate, failed to dephosphorylate either Gwl-phosphorylated Endos or the 
CDKS substrate.  (B-D) Dose-response curves to phosphatase inhibitors (fostriecin, 
tautomycetin, and phosphomimetic Endos S68D as indicated) for the anti-Endos (red circles) 
and anti-CDKS (blue squares) activities of purified PP2A-B55 heterotrimers.  Each point 
represents a single assay (n=1).  The anti-Endos activity of purified PP2A-B55 heterotrimers 
has the same characteristics as the predominant anti-Endos activity in whole cell extracts.  In D, 
the fostriecin used has lost potency during the ~6 months of storage after the experiments 
shown in Figure 2 were performed; fostriecin is well-known to be somewhat labile in this time 
frame (90).  It is nonetheless clear that both the anti-Endos and anti-CDKS functions of PP2A-
B555 display similar dose responses to this drug.  (E) Technical replicates (n=3) of untreated 
purified PP2A-B55 and enzyme treated with the maximal doses of the inhibitors shown in 
panels B-D (20 M fostriecin, 10 M tautomycetin, and 20 M Endos S68D) were performed 
to assess reproducibility; symbols indicate average values and bars representing one standard 
deviation are shown.
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Figure 7.  Determinations of the kinetic parameters shown in Table 1.  (A) Determination 
of kinetic parameters for the dephosphorylation of CDKS and Fzy-Ser50 substrates.  One 
representative experiment is shown.  Initial rates of dephosphosphorylation were determined 
with increasing substrate concentrations; the concentration of purified PP2A-B55 was 1 nM.  
The amount of 32P phosphate released was in all samples less than 20% of the input.  For 
pCDKS substrate, n = 4; for pFzy-Ser50 substrate, n = 3 (technical replicates).  The data were 
analyzed by non-linear regression analysis (using Prism 6 software) to determine Km and kcat 
values incorporated into the data shown in Table 1.  Because we could not obtain sufficiently 
concentrated preparations of the Fzy-Ser50 substrate, the uncertainty in these parameters is 
very high, but the graphs illustrate that the behavior of these two substrates is nonetheless 
much more similar to each other than either is to pEndos.   
(B and C)  Determination of kinetic parameters for the dephosphorylation of pEndos from the 
initial reaction velocity as a function of substrate concentration.  One representative experiment 
is shown.  Initial rates of dephosphosphorylation were determined with increasing substrate 
concentrations. The concentration of purified PP2A-B55 was 0.5 nM; n = 4 technical replicates 
at each substrate concentration point.  The amount of 32P phosphate released was in all samples 
less than 20% of the input.  The data were analyzed by non-linear regression analysis as 
detailed in the Materials and Methods to determine Km and kcat values shown in Table 1.  B and 
C graph the same data at different ranges of pEndos concentration.  Note that in B, the rate of 
pEndos dephosphorylation remains constant near Vmax over a 20-fold range from 50 to 1100 
nM, indicating that pEndos does not inhibit its own dephosphorylation.  (D and E) 
Determination of kinetic parameters for the dephosphorylation of pEndos from competition 
with okadaic acid.  Note the logarithmic scale on the y-axes. (D) Initial rates of pEndos 
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dephosphorylation were determined in the presence of increasing concentrations of okadaic 
acid; one representative experiment is shown.  The amount of 32P phosphate released was in all 
samples less than 20% of the input.  Two independent experiments (technical replicates) are 
indicated with pink squares and green stars.  The concentration of pEndos in this reaction was 
50 nM, the concentration of purified PP2A-B55 was 0.25 nM, and the concentration of okadaic 
acid varied as shown.  The data were fit by non-linear regression analysis to the mathematical 
model described in Materials and Methods; calibration curves based on this model are shown 
in (E).   
 
Figure 8.  Dose-response curves for PP2A-B55 inhibitors.  (A) The ability of PP2A-B55 (at 
0.125 nM) to dephosphorylate radioactive CDKS substrate (at 5 M) was measured in the 
presence of varying amounts of the following inhibitors: okadaic acid (green), 
thiophosphorylated Endos (black), non-radioactive pEndos [during a 30 min incubation (pink) 
and a 120 min incubation (red)], and unphospohorylated Endos (blue).  Thiophosphorylation 
by Gwl kinase makes Endos into a much stronger inhibitor of PP2A-B55 than 
unphosphorylated Endos; the affinity of thiophosphorylated Endos is only about two-fold 
lower than that of okadaic acid.  Non-radioactive pEndos is a less efficient inhibitor of PP2A-
B55 than is thiophosphorylated Endos because the enzyme dephosphorylates pEndos during 
the course of incubation; the longer pEndos is exposed to the enzyme, the higher is the 
concentration of pEndos required to achieve the same degree of inhibition. For all points 
shown, n=3 technical replicates.  (B) Direct demonstration of the automatic reset mechanism 
that allows PP23A-B55 reactivation upon anaphase onset.  PP2A-B55 at 0.25 nM was mixed 
together on ice with buffer in the absence of Endos (control) or in the presence of 16 nM 
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unlabeled Gwl-phosphorylated Endos or Gwl-thiophosphorylated Endos and incubated on ice 
for 5 min; radioactive pCDKS substrate was then added to a final concentration of 0.47 M; 
and the reaction was then transferred to 30°C at t = 0 and aliquots assayed for the release of 32P 
from the pCDKS substrate.  Each point represents the average of three technical replicates (n = 
3) with standard deviations shown.  The dephosphorylation of pCDKS is suppressed until the 
majority of pEndos is inactivated by PP2A-B55-mediated dephosphorylation.  (The gradual 
decrease in the slopes of the control and pEndos-added curves is probably from instability 
and/or degradation of the PP2A-B55 during the extended time-course.) The control and cold 
pEndos data were fitted to curves calculated as described in Materials and Methods; the best fit 
gave Km = 0.47 ± 0.14 nM and kcat = 0.03 sec-1.  The stronger inhibition caused by the 
thiophosphorylated pEndos (green triangles) is expected because its Kd (~0.12 nM) is lower 
than the Km of pEndos. 
 
Figure 9.  Inhibition by unfair competition.  In this model, pEndos and CDK-phosphorylated 
substrates compete for the active site of PP2A-B55.  During M phase, pEndos is in 
stoichiometric excess of PP2A-B55, so due to the disparities in the kinetic constants of these 
substrates, almost all of the enzyme will thus accumulate as a tight-binding complex with 
pEndos.  Although PP2A-B55 can slowly dephosphorylate pEndos, the inhibitor is replenished 
by action of Gwl until this kinase is inactivated at anaphase onset (not shown).   
 
Fig. 10.  Theoretical time-course of pEndos dephosphorylation and PP2A/B55 activation 
at the end of M-phase.  These calculations make three assumptions: (1) Consistent with 
published data (23, 57), Endos was completely phosphorylated during M phase;  (2) Because 
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the Km of PP2A-B55 for pEndos (~1 nM, Table 1) is much smaller than the pEndos 
concentration (1 M), essentially all the PP2A-B55 was bound to pEndos during M phase; and 
(3) The Gwl phosphorylation of Endos stopped at the end of M-phase (t=0) (9, 23, 56, 57).  
The curves show the fraction of Endos that remains phosphorylated (purple) and the fraction of 
PP2A-B55 that is released from pEndos sequestration (orange) as a function of time t in sec.  
(A) Scenario: PP2A-B55 is the only enzyme that can dephosphorylate pEndos.  Parameter 
values estimated from the experimental data were used: Total PP2A/B55 concentration, 250 
nM; initial total pEndos concentration, 1 M; Km, 1 nM; and kcat, 0.05 sec-1.  (B) Scenario: 
pEndos is a target of both PP2A-B55 and equal amounts of PPX, a second phosphatase with 
parameters Km = 85 M and kcat = 22.5 sec-1 (based on the dephosphorylation of pCDKS by 
PP2A-B55 in Table 1).  (C and D) Scenario: pEndos is only an inhibitor and not a substrate of 
PP2A-B55, and only PPX dephosphorylates pEndos.  In this case, the Kd = 0.12 nM of 
thiophosphorylated Endos was used; this value was calculated from the IC50 for 
thiophosphorylated Endos from the dose-response curve in Figure 7 according to the equation 
described in (71, 81).  The time frame in D is an extension of that in C, showing that the time 
required for desequestration of 50% of PP2A-B55 activity would be ~6200 sec. 
 
Figure 11.  Fcp1 is not the anti-Endos phosphatase.  (A and B).  Depletion of Fcp1 does not 
decrease anti-Endos activity.  (A) Control extracts (made from S2 cells treated with a mock 
double-stranded RNA) or Fcp1 RNAi extracts (made from S2 cells treated with double-
stranded RNA corresponding to the Drosophila Fcp1 gene (CG12252) were assayed for 
phosphatase activities using pCDKS, pEndos, and pCTD [the C-terminal domain of RNA 
polymerase II phosphorylated in vitro by mitogen-activated kinase 2 (MAPK2)] substrates. No 
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significant differences were observed in terms of anti-CDKS or anti-Endos activities.  Fcp1 
depletion slightly decreases activity against the CTD substrate, consistent with the fact that 
Fcp1 is only one out of several known phosphatases known to target the CTD (32).  Each bar 
represents the average of three technical replicates with the standard deviation shown.  (B) 
Western blot of the control and Fcp1 RNAi extracts assayed in part A, showing that more than 
90% of the Fcp1 was removed by the treatment with Fcp1 double-stranded RNA.  The loading 
control shows the signal revealed by antibody against the RNA polymerase II elongation factor 
TFIIS.  (C and D).  Purified S. pombe Fcp1 enzyme has minimal anti-Endos activity.  Activities 
of purified Fcp1 against labeled pEndos, pCDKS, and pCTD.  Each point represents a single 
assay.  Note that the concentrations of Fcp1 employed in these experiments are in the 
micromolar range, as opposed to the subnanomolar-to-nanomolar concentrations of purified 
PP2A-B55 used in other figures.  Consistent with previous reports for this enzyme (29), the 
specific activity of Fcp1 against the CTD substrate is low (but much higher than that against 
pEndos).  (E) The activities of purified wildtype Fcp1 against all three substrates are as 
expected resistant to high concentrations of okadaic acid (10 M).  A preparation of kinase-
dead (KD) S. pombe Fcp1 with the D172N mutation (78) made in parallel has no activity 
against any of these three substrates. 
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TABLES 
 
 
TABLE 1.  Kinetic parameters of dephosphorylation by PP2A-B55 
 
Substrate Km  (M) kcat (sec-1) n1 Method2 Representative 
experiment 
      
CDKS 71 - 99 21 - 25 2 v  vs. [S] Figure 7A 
      
Fzy Ser50 >1003 >153 1 v  vs. [S] Figure 7A 
      
pEndos 0.0009 – 0.0017 0.021 – 0.035 
0.018 – 0.0664 
2 
164 
v  vs. [S] Figure 7B,C 
 0.0004 – 0.0011 0.005 – 0.037 3 OA competition Figure 7D,E 
 
1 Number of independent experiments; each point in each experiment included 3-4 
measurements. 
 
2 v vs. [S] experiments measured the initial rate of reaction as a function of substrate 
concentration; OA competition experiments involved measurements of pEndos 
dephosphorylation as a function of okadaic acid competition 
 
3 Because sufficiently high concentrations of the Fzy Ser50 substrate were not obtained, non-
linear regression analysis was inherently inaccurate in determining kinetic parameters.  The 
values given are conservative lower limits. 
 
4 The specific activities of multiple independent preparations of purified PP2A-B55 were 
measured at high pEndos substrate concentrations (5 M) approximately 1000-fold in excess 
of the Km. 
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Legends for Figure Supplements  
 
Figure 2 – figure supplement 1.  Anti-Endos is completely inhibited by okadaic acid and 
calyculin A.  In all parts of this figure, red circles depict anti-Endos, and blue squares are anti-
CDKS; in B and C green triangles represent dephosphorylation activity against Histone H3.  In 
all panels except part D, each symbol represents a single assay. (A and B) Biological replicates 
of the experiment shown in Figure 2B.  (C) Xenopus CSF extracts were untreated (M phase) or 
treated with Ca2+ for 30 minutes (interphase) and then assayed for phosphatase activity.  As in 
Figure 2A, anti-CDKS is undetectable in CSF extracts.  The sensitivity of anti-Endos to 
okadaic acid is similar in M phase and interphase extracts; in both cases, the IC50 for anti-
Endos is about 3-fold higher than that for anti-CDKS in interphase.  We presume this 
difference reflects the substantial fraction of anti-Endos in Xenopus extracts due to PP1 (see 
Figure 2 – figure supplement 2).   (D) In asynchronous S2 (Drosophila) cell extracts, anti-
CDKS and anti-Endos have nearly identical dose-response curves to okadaic acid; these 
activities are slightly more sensitive to okadaic acid than is the phosphatase activity directed at 
Histone H3 substrate.  In this panel, each symbol represents the average of 4 technical 
replicates; error bars are not shown for the anti-CDKS activity to aid readability, but their 
magnitude is consistent with those of the other assays.  (E) Evolutionary replicate of panels A-
D performed with an extract made from asynchronous mouse embryo fibroblast (MEF) cells.  
(F) Phosphatase activities against all three substrates are completely suppressed by calyculin A; 
reported IC50 values for this drug with respect to PP1, PP2A, PP4, PP5, and PP6 are all similar 
(79). 
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Figure 2 – figure supplement 2.  Anti-Endos is mostly fostriecin-sensitive.  In all parts of 
this figure, red circles depict anti-Endos, blue squares are anti-CDKS, green triangles are 
activity against Histone H3, and purple stars are anti-H1v1.0.  Each symbol represents a single 
assay.  (A) The fostriecin sensitivities of anti-Endos in M phase (CSF extracts) and interphase 
Xenopus egg extracts are similar.  A proportion of anti-Endos in these concentrated egg extracts 
is more fostriecin-resistant than is the anti-CDKS in the same extracts; the exact proportion is 
difficult to estimate because the maximal amount of fostriecin that could be added was 
insufficient even to inhibit anti-CDKS completely.  (B-F) In extracts of Xenopus eggs diluted 
1:4 in phosphatase buffer (B), of Drosophila S2 cells (C and D are biological replicates), or of 
mouse MEF cells (F), anti-Endos activity is more resistant to fostriecin than is anti-CDKS, but 
is less resistant than are the phosphatase activities against Histone H1v1.0 or Histone H3.  In 
panel C, two technical replicates of the anti-Endos assay are shown.  These data suggest that 
PP1-like enzymes account for most of the activity against Histone H1v1.0 and about half of 
that against Histone H3.  From the amount of anti-Endos activity remaining at fostriecin 
concentrations of 100 M sufficient to inhibit anti-CDKS completely, we estimate that 70-90% 
of anti-Endos is fostriecin-sensitive (depending on the extract) and is therefore likely to be 
PP2A, PP4, or PP6.  The minor fostriecin-resistant component is labile and is lost from certain 
extracts such as D and E (see also Figure 2C).   
 
Figure 2- figure supplement 3.  Anti-Endos is more tautomycetin/tautomycin-resistant 
than anti-CDKS.  (A)  As expected from the literature (53), purified PP1 (orange stars) is 
more sensitive to tautomycetin than is an equal molar amount of purified PP2A A-C dimer 
(pink diamonds) measured with myelin basic protein phosphorylated with PKA kinase as 
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substrate.  (B-F) The IC50 for tautomycetin (B-E) or tautomycin (F) is consistently ~10-fold 
higher for anti-Endos than for anti-CDKS when measured in the same extract. The activity 
against CDK-phosphorylated Histone H1v1.0 is more sensitive than either to tautomycetin, 
consistent with the argument that the major phosphatase targeting this substrate is PP1.  Each 
data point represents a single assay; C and D are biological replicates using different extracts of 
S2 cells. 
 
Figure 2 –figure supplement 4.  Anti-Endos is resistant to phosphomimetic Endos.  
Although anti-CDKS activity is strongly inhibited by phosphomimetic Endos (S68D), anti-
Endos activity is insensitive to addition of this molecule.  The dephosphorylations of Histone 
H1v1.0 or Histone H3 substrates are also resistant to Endos S68D, as would be expected of 
substrates that are targeted by PP1 or any phosphatases other than PP2A-B55.  Each data point 
represents a single assay; panel A is a biological replicate of the results shown in Figure 2E. 
 
Figure 2 –figure supplement 5.  The specific activity of anti-Endos does not increase upon 
substrate dilution.  The y-axis shows the phosphatase activity on the indicated substrates, 
normalized to the original volume of undiluted extract.  Panel A is a biological replicate of the 
experiment shown in Figure 2F, n=1; in panel B, the data points each represent the average of 
3 technical replicates with error bars shown.  The reason the dilution effect is less pronounced 
for the extract in part A likely reflects the fact that the original concentration of this extract 
(prior to dilution) was about four-fold lower than that in panel A.   
 
Figure 2 – figure supplement 6.   Estimating relative levels of Twins (B55) and Endos 
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proteins in Drosophila S2 cells.  Sequential dilutions of purified recombinant proteins and of 
total S2 cell extracts were compared on Western blots using antibodies against these two 
proteins.  Total protein amounts in extracts were determined by nanodrop spectrophotometry. 
 
Figure 3 – figure supplement 1.  Neither PP4 nor PP5 is a major contributor to anti-
Endos.  (A and B) Treatment of HeLa cells with siRNA to the PP4 catalytic subunit strongly 
reduces the amount of PP4 but does not obviously affect anti-Endos levels.  C1 represents 
control cells that are not treated with siRNA; C2 cells were treated with a control scrambled 
siRNA.  (C and D)  No obvious changes in anti-Endos levels are seen in the mutant mouse 
MEF cells homozygous for a null mutation in the gene encoding the PP5 catalytic subunit (94) 
relative to control MEF cells.  PP5 may be a minor contributor to Histone H3 
dephosphorylation.  In panels A and C, LC are background bands used as loading controls for 
the Western blots.  In panels B and D, the number of technical replicates is indicated in each 
bar. 
 
Figure 6 – figure supplement 1.  Preparations of PP2A heterodimer and heterotrimers.  In 
the first four lanes, HEK cells were transfected with the indicated constructs, and FLAG-
tagged components were affinity purified as described in Materials and Methods.  Final 
preparations were fractionated by SDS-PAGE and analyzed by silver staining (top panel) and 
by Western blot (bottom panels).  The major visible components in the silver staining are the A 
and C subunits of PP2A, the FLAG-tagged regulatory subunit whose expression construct was 
originally transfected (B55, B55, or B56), and bovine serum albumin (BSA) added to 
stabilize the purified enzymes.  An additional band of variable intensity located between the 
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B55 and C bands, which is also seen in the vector alone control lane, was identified by mass 
spectrometry as keratin; yet another weak band seen in some preparations that migrates just 
faster than B55/ appears to be immunoglobulin heavy chain from the anti-FLAG column.  
At the right is a sample of commercially obtained A-C heterodimer (Millipore 14-111). 
 
Figure 6 – figure supplement 2.  Characterization of phosphatase assays using purified 
PP2A-B55.  Panels A and B show the rate at which phosphate is released from labeled 
substrates as a function of the concentration of PP2A-B55.  The relationships are 
approximately linear, although the rate of the anti-Endos reaction slows slightly at higher 
enzyme concentrations; for this reason, the concentration of PP2A-B55 was held to 0.5 nM or 
below in most experiments.  Panels C and D show time courses of the same reactions; the 
concentration of PP2A-B55 was 0.5 nM.  As expected, the reactions slow down as more than 
20% of either substrate is depleted and as the reaction time becomes long enough for the 
PP2A-B55 to lose activity due to instability or degradation.  For these reasons, kinetic 
constants were measured in experiments with incubations sufficiently short to ensure that the 
maximal conversion of substrate stayed below this level and to minimize loss of enzyme 
function.  In all panels, data points represent the average of 3 technical replicates with error 
bars shown. 
 
Figure 10 – figure supplement 1.   PP2A-B55 sequesters pEndos from the action of other 
phosphatases.  The graph models the scenario that cells contain an additional phosphatase 
PPX, present at the same concentration as PP2A-B55 (250 nM), which targets pEndos.  The y-
axis shows the fraction of the total initial rate of pEndos dephosphorylation contributed by the 
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indicated enzyme (red for PPX; blue for PP2A-B55).  The kinetic parameters used for PP2A-
B55 and PPX were identical to those in Figure 9.  When the concentration of pEndos is below 
the intracellular concentration of PP2A-B55, the contribution of PPX to pEndos 
dephosphorylation is negligible.   
 
 
 





















